TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Russia preparing mass vaccination against coronavirus for October
Change Size
A medical worker wearing protective equipment takes a swab from a woman at a medical facility in Moscow on July 16, 2020, on the first day the Russian capital started providing free testing for the coronavirus disease to its residents. (AFP/Kirill KUDRYAVTSEV )
R
ussia's health minister is preparing a mass vaccination campaign against the novel coronavirus for October, local news agencies reported on Saturday, after a vaccine completed clinical trials.
Health Minister Mikhail Murashko said the Gamaleya Institute, a state research facility in Moscow, had completed clinical trials of the vaccine and paperwork is being prepared to register it, Interfax news agency reported.
He said doctors and teachers would be the first to be vaccinated.
"We plan wider vaccinations for October," Murashko was quoted as saying.
A source told Reuters this week that Russia's first potential COVID-19 vaccine would secure local regulatory approval in August and be administered to health workers soon thereafter.
The Gamaleya Institute has been working on an adenovirus-based vaccine.
Yet the speed at which Russia is moving to roll it out has prompted some Western media to question whether Moscow is putting national prestige before science and safety.
The head of the Russian Direct Investment Fund, Kirill Dmitriev, has likened what he said was Russia's success in developing a vaccine to the Soviet Union's 1957 launch of Sputnik 1, the world's first satellite.
On Saturday, Russia reported 95 additional deaths from the novel coronavirus, taking its total to 14,058.
Officials reported 5,462 new cases, raising the total to 845,443.
More than 100 possible vaccines are being developed around the world to try to stop the COVID-19 pandemic.
At least four are in final Phase III human trials, according to World Health Organization (WHO) data, including three developed in China and another in Britain.
